NASDAQ · ARCT
Arcturus Therapeutics Holdings Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ARCT: Nov 05, 2026
Arcturus Therapeutics Holdings Inc. Common Stock is expected to report earnings on 11/05/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.6. The reported EPS for the same quarter last year was $-0.49.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.60 | $-0.29 | $-0.87 | 4 |
| Dec 2026 | $-1.01 | $-0.76 | $-1.55 | 4 |
| Mar 2027 | $-0.89 | $-0.89 | $-0.89 | 1 |
| Jun 2027 | $-0.91 | $-0.91 | $-0.91 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · MarketBeat · Fintel- Zacks · Oct 23, 8:40 AM EDTAre Medical Stocks Lagging Agilon Health (AGL) This Year?Here is how Agilon Health (AGL) and Arcturus Therapeutics (ARCT) have performed compared to their sector so far this year.
- RTTNews · Sep 29, 10:41 AM EDTArcutis Partners With Simone Biles To Raise Awareness Of Skin Conditions(RTTNews) – Arcutis Biotherapeutics (ARQT) said World Champion gymnast Simone Biles has partnered with the company to launch the Skin to Believe In awareness campaign, focused on seborrheic dermatitis and eczema.
- Zacks · Sep 28, 9:57 AM EDT4 RNA Therapeutics Stocks Leading the Next Wave of InnovationRNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
- MarketBeat · Sep 24, 11:02 PM EDTArcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy PlatformArcturus Therapeutics (NASDAQ:ARCT) presented preliminary Phase II data for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase, or OTC, deficiency, while outlining plans to introduce a next-generation delivery platform into the program. OTC deficiency is a u
- RTTNews · Sep 24, 3:06 PM EDTBiotech Stocks On The Move – APUS, PFSA, GCTK, ARCT(RTTNews) – The following biotech stocks were in focus on September 24, 2026, following notable stock moves and company-specific developments involving clinical programs, regulatory progress, financing and technology platforms.
- Fintel · Sep 14, 9:31 PM EDTArcturus Therapeutics Holdings Consensus Price Target Increased by 14.69% to $22.75The average one-year price target for Arcturus Therapeutics Holdings (NASDAQGM:ARCT) has been revised to $22.75 / share. This is an increase of 14.69% from the prior estimate of $19.83 dated August 25, 2026. These figures represent aggregate analyst targets compiled as of Septem
- Zacks · Aug 27, 9:55 AM EDTArcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?Is it a good or bad thing when a stock experiences a golden cross technical event?
- RTTNews · Aug 21, 2:09 PM EDTArcturus Q2 Loss Widens; ARCT-032 Phase 3 Decision Expected In Q4 2026(RTTNews) – Arcturus Therapeutics Holdings Inc. (ARCT), a messenger RNA medicines company focused on liver and respiratory rare diseases, recently reported second-quarter 2026 financial results and provided pipeline updates.
- The Motley Fool · Aug 13, 8:02 PM EDTArcturus (ARCT) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 11, 9:04 PM EDTArcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds PipelineArcturus Therapeutics (NASDAQ:ARCT) is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is intended to help support therapeutic development, President and CEO Joseph Payn
- MarketBeat · Aug 6, 6:04 PM EDTArcturus Therapeutics Q2 Earnings Call HighlightsArcturus Therapeutics (NASDAQ:ARCT) reported progress across its rare-disease pipeline during the second quarter of 2026, completed enrollment and dosing in its Phase II ornithine transcarbamylase deficiency study, and regained global rights to its KOSTAIVE COVID-19 vaccine and s
- Zacks · Aug 6, 5:20 PM EDTArcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue EstimatesArcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +21.50% and +18.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Arcturus Therapeutics Holdings Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.